Psychosis: Impact on the patient and family

Neurology

Volumn 52, Issue 7 SUPPL., 1999, Pages

  Melamed, Eldad ^a   Friedberg, Gali ^a   Zoldan, Joseph ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; SEROTONIN ANTAGONIST;

AGGRESSION; AGITATION; CONFUSION; CONSTIPATION; DELIRIUM; FAMILY LIFE; HALLUCINATION; HEADACHE; HUMAN; NIGHTMARE; PARANOID PSYCHOSIS; PARKINSON DISEASE; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; WEIGHT REDUCTION;

FAMILY; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 0033594453     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. Zoldan Y, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993;341:562-563.
2. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995;45:1305-1308.